Urteste S.A.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2021-03-02
Share capital
163,278.00 PLN
Activity description

Urteste is developing the world's first method for detecting multiple cancers from a single urine sample. This early cancer detection technology aims to enable effective treatment by identifying the disease at an early stage.

Registered address
ul. Starodworska 1, 80-137 Gdańsk, Poland
Electronic delivery address
AE:PL-66021-48593-SJJTT-14

Financials

Revenue history (in k)

Filing timeliness

4 of 5 financial statements were filed late (the longest delay 83 days for 2025). All were audited by a statutory auditor.

  • 202506/10/2026
  • 202405/07/2025
  • 202327/07/2024
  • 202205/09/2023
  • 202121/07/2022
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 51.20
-0.80 (-1.54%)
46.0048.0050.0052.0051.2010:0012:0014:0016:00
Open
PLN 50.40
High
PLN 52.80
Low
PLN 46.00
Volume
1.88K
Avg. vol.
1.46K
Market cap
PLN 78.14M
P/E ratio
–
EPS
-PLN 2.37
Shares outstanding
1.53M
52-week
PLN 39.90 – 57.60
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 810.37USD 501.62kUSD 489.20k
Q1 2026–USD -488.11kUSD -501.62k
Q4 2025–USD -461.07kUSD -473.88k
Q3 2025–USD -421.15kUSD -422.15k

Results for Q3 2026:Nov 30, 2026

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 18%
City · Gdańsk2,427 / 7,519
Top 32%
Voivodeship · Pomorskie7,192 / 20,095
Top 36%
Country · Poland107,077 / 298,026
Top 36%

Results vs industry

Revenue
This companyUSD 701.91kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -1.50mMedianUSD -1.27kAverageUSD -92.87k
Operating costs
This companyUSD 2.14mMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 11.34mMedianUSD 134.71kAverageUSD 3.04m

Websites

  • espicore.plEspiCore 2.0 – system wczesnego ostrzegania ESPI
    Cloudflare

Trademarks

The company holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2021.

MarkNumberClassesStatusProtected until
URTESTE (word)Z.5234995Protected Jan 22, 2031
MarkProtected until
URTESTE (word)Jan 22, 2031

Authorized Representatives

Christian Pangratz – President of the Management Board
Grzegorz Stefański age 56 – Management Board Member
Tomasz Jan Kostuch age 56 – Management Board Member

Manner of representation

In the case of a one-person management board as well as a multi-member management board, each member of the management board is authorised to make declarations within the scope of the company’s rights and obligations independently.

Supervisory board

Grzegorz Basak age 48 – Supervisory Board Member
Jarosław Biliński age 40 – Supervisory Board Member
Maciej Matusiak age 59 – Supervisory Board Member
Magdalena Wysocka age 47 – Supervisory Board Member
Przemysław Piotr Mencel age 55 – Supervisory Board Member

Beneficial owners

Person

Sanctions and PEP

Sanctions

No matches (EU, UN, US, UK, MSWiA, World Bank)

PEP

No matches

Bank accounts

Registered as a VAT taxpayer on 2019-06-08.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Apr 29, 2021Transformation registered

Public aid

11 public aid cases recorded, with a total value of $14,588,265.

PurposeGross amount
Aid for research and development projects: experimental development
–
Aid for research and development projects: industrial research
–
Aid for SMEs for innovation support
–

European Funds

4 projects co-financed from European Funds recorded, with total EU co-financing of $14,580,706.

ProjectEU co-financing
NASTRO test – a low-cost, enzyme-based IVD test for diagnosing breast cancer in its early stages, international protection of industrial property rights for a new breast diagnostic marker, and acquisition and development of URTESTE S.A. team competencies in R&D and commercialisation
$2.9M
PANURI Test – a highly effective, low-cost enzyme-based IVD test for diagnosing pancreatic cancer in its early stages, and international protection of industrial property rights for inventions in the form of enzyme-based IVD tests for detecting other cancers.
$9.1M
Diagnostic test for detecting pancreatic cancer at an early stage of development.
$2.6M

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Scope Fluidics S.A.
Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o.
Toxlab sp. z o.o.
Nanogroup S.A.
Fileclo sp. z o.o.
Precisionlife Poland sp. z o.o.
Human Biome S.A.
Pharmena S.A.
Lbs-Laboratorium Badań Sądowych sp. z o.o.
Vaxican sp. z o.o.

Change history

DateEvent
2026-11-17Share capital increase
2026-09-07Share capital increase
2023-06-07Share capital increase
2022-04-01Share capital increase
2021-08-12Share capital increase

FAQ

Last updated: 2026-11-17